STAT3 and pancreatic neoplasm: Accordingly, dasatinib (SRC inhibitor) and erlotinib (EGFR inhibitor) treatment reduces pancreatic cancer cell migration and invasion, overcomes STAT3-mediated chemoresistance, and attenuates the growth of PDAC xenografts [79].